SanBio Co (TSE:4592) Cash And Cash Equivalents : 円4,454.72 Mil (As of Jan. 2024)

View and export this data going back to 2015. Start your Free Trial

What is SanBio Co Cash And Cash Equivalents?

SanBio Co's quarterly cash and cash equivalents declined from Jul. 2023 (円4,624.47 Mil) to Oct. 2023 (円3,806.15 Mil) but then increased from Oct. 2023 (円3,806.15 Mil) to Jan. 2024 (円4,454.72 Mil).

SanBio Co's annual cash and cash equivalents increased from Jan. 2022 (円4,557.01 Mil) to Jan. 2023 (円6,732.78 Mil) but then declined from Jan. 2023 (円6,732.78 Mil) to Jan. 2024 (円4,454.72 Mil).

SanBio Co Cash And Cash Equivalents Historical Data

The historical data trend for SanBio Co's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SanBio Co Cash And Cash Equivalents Chart

SanBio Co Annual Data

Trend

Jan15

Jan16

Jan17

Jan18

Jan19

Jan20

Jan21

Jan22

Jan23

Jan24

Cash And Cash Equivalents

Get a 7-Day Free Trial

13,646.07

12,480.17

4,557.01

6,732.78

4,454.72

SanBio Co Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
Cash And Cash Equivalents	Get a 7-Day Free Trial															6,732.78	5,682.16	4,624.47	3,806.15	4,454.72

SanBio Co Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

SanBio Co (TSE:4592) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

SanBio Co Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of SanBio Co's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

SanBio Co (TSE:4592) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SanBio Co Ltd (TSE:4592) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

SNBIF:USA

Address

8-1 Street Luke Tower 32nd Floor, Akashi-cho, Chuo-ku, Tokyo, JPN, 104-0044

Website

https://www.sanbio.com

SanBio Co Ltd is engaged in the research and development of regenerative cells drugs. The company has three types of drugs under development, including nerve regeneration cell SB623, used for the treatment of chronic cerebral infarction, traumatic brain injury, age-related macular degeneration, retinitis pigmentosa, Parkinson's disease, spinal cord injury and Alzheimer's disease; enhanced type-mesenchymal stem cells SB618, used to treat peripheral neuropathy, as well as muscle stem cells SB308, used in the treatment of muscular dystrophy.

SanBio Co (TSE:4592) Headlines

No Headlines